06:36 AM EST, 11/13/2026 (MT Newswires) -- The European Medicines Agency's Committee for Medicinal Products for Human Use recommended the approval of SFL Pharmaceuticals Deutschland's Aumseqa for non-small cell lung cancer, or NSCLC. Aumseqa, or aumolertinib, improves the progression-free survival of patients with advanced NSCLC, compared with gefitinib monotherapy, according to a Friday notice. It is intended for NSCLC patients whose tumors have EGFR exon 19 deletions or exon 21 substitution mutations, and those with EGFR T790M mutation-positive NSCLC. The drug is subject to final approval from the European Commission.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.